[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8,"_9":10},"actionData","errors","root",{"_105":106,"_107":59},"routes/en-gate",{"_104":59},"en-item",{"_11":12},"item",{"_13":14,"_15":16,"_17":18,"_19":-5,"_20":-5,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":27,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":-5,"_40":42,"_43":-5,"_44":-5,"_45":-5,"_46":47,"_48":49,"_50":-5,"_51":52,"_53":54,"_55":56,"_57":38,"_58":59,"_60":-5,"_61":62,"_63":64,"_65":38,"_66":38,"_67":68},"id","o22fsoidwwp6jqucndqvixbxp","revision",1,"title","🚨 #ESMO26 | Post-IO NSCLC","originalTitle","summary","reason","source",{"_13":98,"_78":99,"_100":101,"_102":38,"_103":-5},"links",{"_95":96,"_68":97},"publishedAt","2026-10-25T07:49:33.000Z","discoveredAt","2026-10-25T07:53:12.982Z","timelineAt","category","opinion","tags",[],"score",70,"selected",false,"channel","x","story",{"_86":87,"_88":49,"_89":-5,"_90":-5,"_91":92,"_93":94},"insight","digest","conferenceAbstracts","readingMode","full","author","OncologyMarwarD","language","body",{"_82":-5,"_68":83,"_84":-5,"_85":59},"outline",[],"relatedStories",[],"indexable","markdownAvailable",true,"group","conference",{"_76":77,"_78":79,"_80":-5,"_81":-5},"engagement",{"_69":70,"_71":70,"_72":70,"_73":70,"_74":75},"posterIsAuthor","hasTranslation","bodyLanguage","original","heat",0,"likes","replies","reposts","views",3,"slug","esmo-2026","name","ESMO Congress 2026","topic","reading","zh","

🚨 #ESMO26 | Post-IO NSCLC

🔹 Pumitamig + docetaxel: ORR 36.7%, mPFS 6.9 mo (Phase II).

🔹 CS2009 + docetaxel: ORR 55.6%, DCR 100% (n=18).

Promising dual/triple immune-angiogenic targeting strategies! ⚠️ Small, nonrandomized cohorts; no head-to-head comparison.

#LungCancer

","zhKind","complete","authorName","OsmanKostekMD","handle","avatarUrl","quoted","thread",[],"media",[],"aihot","/items/o22fsoidwwp6jqucndqvixbxp","https://x.com/OncologyMarwarD/status/2114263076639756485","esmo26-floor","x.com","kind","x_search","firstParty","iconUrl","ok","changelogVersion","2026-10-24T20:30","enEditionEnabled"]